Significant changes in New Zealand’s legislation in 2018 have paved the way for the creation of a fully commercialised medical and nutraceutical cannabis industry. Medical Kiwi is in a unique position as one of a handful of New Zealand companies poised to create value and carve out a significant share of this emerging and exciting growth industry. The global opportunity that medicinal cannabis represents is estimated to reach USD $150 billion by 2025.
(Grand View Research, April 2018)
Medical Kiwi has a clear strategy for research, manufacturing, product, marketing, sales and distribution and an experienced Board of Directors with vast knowledge and expertise. This has put Medical Kiwi in the premier position to realise the global opportunities for a New Zealand produced and branded high quality, safe, effective and affordable medicinal and nutraceutical products to effect real changes in people’s lives and health outcomes.
Medical Kiwi exists to enable those suffering from illness, seeking alternative pain management and improved wellbeing to have access to safe, effective, affordable high-quality medicinal and nutraceutical cannabis products.
The positive effects of medicinal cannabis in improving the lives of people overseas are well documented and research is now emerging to support this. Internationally, scientists are conducting pre-clinical and clinical trials to test the efficacy of cannabis and its extracts to treat diseases that affect the immune system, inflammation, pain, seizures and psychological disorders.